胸部肿瘤学

胸部肿瘤学 姓名 傅剑华 年龄 42 学科、专业 胸部肿瘤学 Date of Surgical Oncology Name Fu Jianhua 06,Jan,1965 Major birth of Thorax 教授/主任医020－87343392 020－87343628 职称 传真 联系电话 师 Current 020－87343392 020－87343628 Professor Fax Tel position 电子邮件 fjh@medmail.com.cn E-mail fjh@medmail.com.cn （包括研究方向及专业特长等Please include the field of research and speciality.） 精通胸部常见肿瘤包括：食管癌、肺癌、乳腺癌、纵隔肿瘤等的外科诊治 及综合治疗，对胸部肿瘤非血管介入手术、早期食管癌内镜微创手术等有较深 的造诣。1990年在国内首先报道“经口食管腔内置管术治疗晚期食管癌”，1996年在广东省内领先开展了“气管支气管支架的临床应用研究”，同期在国内首次提出“选择性程式治疗食管重建术后食管胃吻合口良性狭窄”。曾参与或主持与食管癌、肺癌有关的国家“973”攻关课题和多项省、厅级研究课题。迄今已 发论文30余篇。获省级广东省科学技术研究成果两项，已授权发明专利两项。 研究方向： 1.食管癌的综合治疗的临床研究及相关基础研究 2.食管癌的临床分期及分子分期 3.记忆金属食管良性支架及人工食管的研制及产业化 Professor Fu is proficient at the diagnosis and surgical and multidisciplinary synthetic treatment of thoracic tumors, including esophageal carcinoma, lung cancer, breast cancer, mediastinal cancer and so on, and has further attained great achievement in non-vascular interventional therapy for thoracic tumors and minimal invasive surgery for esophageal tumor under the endoscope. His research the operation of placing oesophagus bracket through mouth for treatment of late stage esophageal carcinoma was published in 1990 for the first time in China. And he was the first one that carried out the clinical application trials of tracheobronchial stenting in Guanddong province, and pointed out Selective therapeutic modalities for benign anastomotic strictures following esophageal reconstruction in China in 1996. He has ever participated in or presided over the National 973 plan and several province and health department research works related to esophageal and lung cancer, and published more than thirty papers till now. Professor Fu has received a number of national and local honors in recognition of career achievements. Among those are two rewards for scientific and technological achievement and two authorized invention patents. Now Professor Fu’s research is focused on the fields of the clinical and related basic medical research of multidisciplinary synthetic treatment for esophageal carcinoma, the clinical and molecular stages of esophageal carcinoma, and the research and industrialization of memory metallic esophagus benign stent and artificial esophagus. *.食管癌的综合治疗个体化的相关基础研究 目前，外科手术是食管癌的主要治疗手段，虽然单一治疗（包括 手术、放疗、化疗）在局部病变的控制方面有一定效果，但由于大部 分患者在就诊时已为肿瘤进展期或具有远处转移，食管癌治疗后的5 年生存率在近30年没有显著提高。近年来众多的临床随机对照研究提 示综合治疗（包括新辅助化疗、术前同期放化疗及序贯放化疗等）可 以提高食管癌患者的生存率。但是，由于肿瘤异质性的原因可能造成 同一临床分期、病理类型和采用相同治疗的肿瘤病人其治疗效果、 生存期存在明显的不同。因此，目前的研究主要针对肿瘤的个体异质 性，寻找可用于预测食管癌患者治疗反应、预后的分子标志，并进一 步开展相关基因及蛋白的功能和机制研究，为将来针对不同患者肿瘤 分子表型发展合理的临床综合治疗方案或为分子靶向治疗的发展奠定 基础。 Nowadays, surgery is the most common approach to treat patients with localized carcinoma of the esophagus. Although several adjuvant treatment methods such as radiotherapy and chemotherapy have been adopted in clinical practice beside surgery, the 5-year survival rates of patients with carcinoma of esophagus continues to be poor. Recently, some clinical random control trials suggest that multidisciplinary synthetic therapy, including neoadjuvant chemotherapy or chemoradiotherapy with surgery improve the survivals of patients. But due to the heterogeneity of the neoplasms, not all of the patients even those who are of the same clinical stage, histological type and receive the same treatment protocol could obtain benefits from the therapies. Consequently, our research work intends to find out the bio-markers which would determine the heterogeneity of the esophageal carcinomas and could be used in predicting patients’ responses to treatments and prognoses, and to understand the molecular functions and mechanisms of related genes and proteins, and further to prepare the ground for developing reasonable clinical multidisciplinary synthetic therapy and the molecular target therapies.